Osteomin Mechanism of Action

Pharmacology: Glucosamine sulphate is stimulating proteoglycan synthesis, inhibiting the degradation and also stimulating the regeneration of experimentally-induced cartilage damage.
Chondroitin sulphate is increased joint glycoaminoglycan concentration and a subsequent enhancement of synovial fluid viscosity. Improvement in joint structure and function by increasing endogenous synthesis of hyaluronic acid and sulphated glycoaminoglycans and reducing breakdown of joint glycoaminoglycans subsequent to decreased collagenolytic activity and inhibition of enzymes which are capable of degrading existing joint glycoaminoglycans.
Pharmacokinetics: Glucosamine sulphate as oral administration, the peak was reached at the 9th hour after administration. The elimination half-life is 58 hours. The absolute oral bioavailability is 44%. The fecal excretion in 120 hour was 11.3% of the administered dose showing that at least 88.7% of the administered dose was absorbed through the gastrointestinal tract.
Chondroitin sulphate can be absorbed orally. The bioavailability of chondroitin sulphate ranges from 15% to 24% or the orally administered dose, 10% is in the form of chondroitin sulphate and 90% in the form of depolymerized derivatives with a lower molecular weight. Chondroitin sulphate is a slow-acting drug for the treatment of osteoarthritis, characterized by a slow onset of action, with a maximal effect being attained after several months of treatment with a carryover effect that persists after cessation of therapy.